reportingrisk.com← the monitorSEC reporting failures, scored and checked against what happened next

Or browse all companies A–Z.

TuHURA Biosciences, Inc./NV

HURA · Nasdaq

No reporting failures in the last 12 months

It filed on time and stood behind its numbers. Of companies scoring zero, 4.0% were delisted, went bankrupt, restated or stopped filing within the following year.

$111Mpublic float
2025-01-03most recent failure

Score over time

012202220232024202520262024-10-01 · score 12024-09-30 filed late (10-K) · going concern2025-01-01 · score 12024-09-30 filed late (10-K) · going concern2025-04-01 · score 22025-01-03 auditor change2024-09-30 filed late (10-K) · going concern2025-07-01 · score 22025-01-03 auditor change2024-09-30 filed late (10-K) · going concern2025-10-01 · score 12025-01-03 auditor change2026-01-01 · score 12025-01-03 auditor change

Hover or tap a dot to see the filings behind that score.

Why they said they were late

Kintara Therapeutics, Inc. (the “ Company ”) has determined that it is unable to file the Annual Report on Form 10-K for the year ended June 30, 2024 (the “ Form 10-K ”) within the prescribed time period without unreasonable effort or expense. The Company had cash and cash equivalents of approximately $4.9 million at June 30, 2024 and, as previously disclosed, based on recurring losses and negative cash flow from operations, as well as current cash and liquidity projections, the Company has concluded that there is a substantial doubt about the Company’s ability to continue as a going concern. As previously disclosed, on April 2, 2024, the Company entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Kayak Mergeco, Inc., a wholly-owned subsidiary of the Company incorporated in the State of Delaware (“ Merger Sub ”), and TuHURA Biosciences, Inc., a Delaware corporation (“ TuHURA ”), providing for, among other things, the merger of Merger Sub with and into TuHURA (the “ Merger ”), with TuHURA surviving the Merger as a wholly-owned subsidiary of the Company. The Company scheduled a special meeting of stockholders for September 20, 2024 (the “Special Meeting”) to approve the proposals to effectuate the Merger, with the closing of the Merger to be completed as promptly as practicable after obtaining such approval. On September 20, 2024, the Company convened and adjourned the Special Meeting to October 4, 2024 as there were insufficient votes for approval of certain proposals to effectuate the Merger. Either party will have the right to terminate the Merger Agreement if the Merger is not consummated on or before November 1, 2024

NT 10-K, filed 2024-09-30 · going concern

What it filed

2025-01-03auditor changed or resigned SEC →

2024-09-30filed late (10-K)going concern SEC →

Kintara Therapeutics, Inc. (the “ Company ”) has determined that it is unable to file the Annual Report on Form 10-K for the year ended June 30, 2024 (the “ Form 10-K ”) within the prescribed time period without unreasonable effort or expense. The Company had cash and cash equivalents of approximately $4.9 million at June 30, 2024 and, as previously disclosed, based on recurring losses and negative cash flow from operations, as well as current cash and liquidity projections, the Company has concluded that there is a substantial doubt about the Company’s ability to continue as a going concern. As previously disclosed, on April 2, 2024, the Company entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Kayak Mergeco, Inc., a wholly-owned subsidiary of the Company incorporated in the State of Delaware (“ Merger Sub ”), and TuHURA Biosciences, Inc., a Delaware corporation (“ TuHURA ”), providing for, among other things, the merger of Merger Sub with and into TuHURA (the “ Merger ”), with TuHURA surviving the Merger as a wholly-owned subsidiary of the Company. The Company scheduled a special meeting of stockholders for September 20, 2024 (the “Special Meeting”) to approve the proposals to effectuate the Merger, with the closing of the Merger to be completed as promptly as practicable after obtaining such approval. On September 20, 2024, the Company convened and adjourned the Special Meeting to October 4, 2024 as there were insufficient votes for approval of certain proposals to effectuate the Merger. Either party will have the right to terminate the Merger Agreement if the Merger is not consummated on or before November 1, 2024

About this score

reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.

Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.

See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.

Every item above is a filing this company made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not investment advice

reportingrisk.com← back to the monitorAll companies A-Z · RSS · found an error? hello@reportingrisk.com